Serum leptin and its relationship with psychopathology in schizophrenia.

Leptin plays an important role in the modulation of the dopaminergic system and has recently been implicated in schizophrenia. There have been conflicting reports on leptin levels in schizophrenia; as well as on the association between leptin levels and clinical symptoms. Therefore, this study aims to examine (i) leptin levels in schizophrenia relative to control, and (ii) the relationship between leptin and symptoms in schizophrenia. One hundred participants with schizophrenia and 89 healthy controls were recruited from the Institute of Mental Health in Singapore. Demographic information and medical histories were collected. Schizophrenia symptoms were assessed using the positive and negative syndrome scale (PANSS) and serum leptin was measured using a commercially available bioplex leptin assay. Linear regressions were performed to examine the relationship between serum leptin and the positive, negative, general psychopathology subscales and total PANSS scores. Contrary to previously published literature, we did not find any significant difference in leptin level between participants with schizophrenia compared to controls, which might be the result of recruited controls being of comparable body mass index. Serum leptin was found to be positively associated with positive symptoms, general psychopathology and total PANSS score. This study provides evidence to suggest a positive association between serum leptin level and symptomatology in schizophrenia. However, since conflicting results in this area of research exist, it is important to understand better the mechanism behind this relationship and to examine temporal fluctuations in leptin levels in relation with changes in clinical symptomatology.